Skip to main content Accessibility help
×
Home
Hostname: page-component-78dcdb465f-w78fb Total loading time: 0.455 Render date: 2021-04-16T12:27:40.344Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Article contents

Efficacy of memantine in schizophrenic patients: A systematic review

Published online by Cambridge University Press:  23 March 2020

M.C. Spano
Affiliation:
Department of Neuroscience, chair of Psychiatry, University “G. d’Annunzio”, Department of Neuroscience Imaging and Clinical Science, Chieti, Italy
M. Lorusso
Affiliation:
Department of Neuroscience, chair of Psychiatry, University “G. d’Annunzio”, Department of Neuroscience Imaging and Clinical Science, Chieti, Italy
G. Baroni
Affiliation:
Department of Neuroscience, chair of Psychiatry, University “G. d’Annunzio”, Department of Neuroscience Imaging and Clinical Science, Chieti, Italy
G. Di Iorio
Affiliation:
Department of Neuroscience, chair of Psychiatry, University “G. d’Annunzio”, Department of Neuroscience Imaging and Clinical Science, Chieti, Italy
M. diGiannantonio
Affiliation:
Department of Neuroscience, chair of Psychiatry, University “G. d’Annunzio”, Department of Neuroscience Imaging and Clinical Science, Chieti, Italy

Abstract

Introduction

Several evidences support the hypothesis that glutamatergic dysfunction may be implicated in the pathogenesis of schizophrenia and in the last few year great interest has been focused on the role of the N-methyl-D-aspartate receptor (NMDAR). Memantine is a noncompetitive NMDARs antagonist, binds the same site of NMDARs of Mg2+, endogenous blocker of NMDARs, with moderate affinity, rapid unblocking kinetics and strong functional voltage-dependency. Memantine does not affect the physiological activation of NMDARs whereas it blocks the sustained activation under pathological conditions. Preclinical studies have demonstrated that memantine at high concentrations targets many receptors, including serotonin, nicotinic acetylcholine, sigma-1 and serotonin and dopamine receptors.

Objectives

Increasing interest in memantine add-on therapy in schizophrenic patients with negative and cognitive symptoms may suggest that memantine could be a new promising treatment in schizophrenia.

Aims

The aim of this update was to evaluate clinical data about the memantine effectiveness in schizophrenic patients.

Methods

We searched on PubMed to identify original studies about the use of memantine in treatment of schizophrenic patients. The search conducted on June 16th, 2016 yielded 135 records. Neuf papers met our inclusion criteria.

Results

Negative symptoms improved in the large majority of patients treated, however there is not a clear evidence on cognitive and positive symptoms (Table 1)

Conclusions

Memantine therapy in schizophrenic patients has given unclear results. It seems that memantine improves mainly negative symptoms, while cognitive and positive symptoms did not improve significantly. Further trials with a more numerous sample are required obtain an objective result.

Table 1

Observation during Memantime administration.

↓: reduction in severity of symptoms; -: no relevant modifications; +: onset of new symptoms

Disclosure of interest

The authors have not supplied their declaration of competing interest.

[]
Type
e-Poster Viewing: Schizophrenia and other psychotic disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 10 *
View data table for this chart

* Views captured on Cambridge Core between 23rd March 2020 - 16th April 2021. This data will be updated every 24 hours.

You have Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Efficacy of memantine in schizophrenic patients: A systematic review
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Efficacy of memantine in schizophrenic patients: A systematic review
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Efficacy of memantine in schizophrenic patients: A systematic review
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *